高级检索
    徐菲, 李培勇. 瑞波西利联合内分泌治疗用于绝经前侵袭性HR+/HER2-晚期乳腺癌患者：随机Ⅱ期RIGHT Choice试验[J]. 循证医学, 2023, 23(2): 92-95. DOI: 10.12019/j.issn.1671-5144.2023.02.006
    引用本文: 徐菲, 李培勇. 瑞波西利联合内分泌治疗用于绝经前侵袭性HR+/HER2-晚期乳腺癌患者：随机Ⅱ期RIGHT Choice试验[J]. 循证医学, 2023, 23(2): 92-95. DOI: 10.12019/j.issn.1671-5144.2023.02.006
    shu
    XU Fei, LI Pei-yong. Randomized Phase Ⅱ RIGHT Choice Trial of Premenopausal Patients With Aggressive HR+/HER2- Advanced Breast Cancer Treated With Ribociclib and Endocrine Therapy[J]. Journal of Evidence-Based Medicine, 2023, 23(2): 92-95. DOI: 10.12019/j.issn.1671-5144.2023.02.006
    Citation: XU Fei, LI Pei-yong. Randomized Phase Ⅱ RIGHT Choice Trial of Premenopausal Patients With Aggressive HR+/HER2- Advanced Breast Cancer Treated With Ribociclib and Endocrine Therapy[J]. Journal of Evidence-Based Medicine, 2023, 23(2): 92-95. DOI: 10.12019/j.issn.1671-5144.2023.02.006
    shu

    瑞波西利联合内分泌治疗用于绝经前侵袭性HR+/HER2-晚期乳腺癌患者：随机Ⅱ期RIGHT Choice试验

    Randomized Phase Ⅱ RIGHT Choice Trial of Premenopausal Patients With Aggressive HR+/HER2- Advanced Breast Cancer Treated With Ribociclib and Endocrine Therapy

      摘要
      • HTML全文
      • 参考文献(8)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回